View on Pubmed.gov 42756013 | View on doi.org 10.3389/fimmu.2... | View the free full text Full text
Reduced circulating anti-CXCR3 antibodies as a common hallmark bridging systemic autoimmunity and atherosclerosis.
- Area of Immunology, Department of Functional Biology, Faculty of Medicine, University of Oviedo, Oviedo, Spain.
- Basic and Translational Research on Inflammatory Diseases, Department of Metabolism, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
- Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Department of Neurology, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain.
- CellTrend GmbH, Luckenwalde, Germany.
- Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
Abstract
INTRODUCTION
immune dysregulation underlies cardiovascular risk excess in systemic autoimmune diseases, such as rheumatoid arthritis (RA) and Sjögren disease (SjD). However, exact mediators are unknown. Regulatory autoantibodies targeting G protein-coupled receptors, including CXCR3, have emerged as modulators of immune and vascular homeostasis, but their role in autoimmunity remains ill-defined. Our aim was to evaluate anti-CXCR3 levels in systemic autoimmunity and their potential value as biomarkers.
METHODS
anti-CXCR3 IgG serum levels were quantified in early RA (n=84), clinically-suspect arthralgia (n=14), and controls (n=65). Established RA (n=103) and SjD (n=44) were recruited for validation. Atherosclerosis was assessed by carotid ultrasound. Cytokines were measured by multiplex immunoassays. Cardiometabolic-related proteins were evaluated using high-throughput targeted proteomics. Publicly available datasets were used for validation.
RESULTS
anti-CXCR3 antibodies were significantly reduced in early RA and clinically-suspect arthralgia compared with controls, independently of disease activity, autoantibodies, or systemic inflammation. This finding was confirmed in the validation cohort. Equivalent results were also observed in SjD. Anti-CXCR3 were negatively associated with good therapeutic outcomes upon csDMARD at 6 and 12 months in early RA. Lower anti-CXCR3 levels were independently associated with atherosclerosis occurrence and extent across conditions. Incorporating anti-CXCR3 into mSCORE improved risk stratification. Anti-CXCR3 were related to proteomic signatures linked to immune activation and to apoptosis, chemotaxis, and cell adhesion in an atherosclerosis-dependent manner in RA and SjD. Transcriptomic analyses indicated compartment-specific CXCR3 dysregulation both in RA and SjD.
CONCLUSION
reduced anti-CXCR3 antibodies represent a shared hallmark bridging systemic autoimmunity and atherosclerosis burden, shaping our understanding on the regulatory role of antibodies at the vascular-immune interface. Clinical translation of anti-CXCR3 antibodies hold promise to improve risk stratification.
References
Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. (2024) 21:780–807. doi: 10.1038/s41569-024-01045-7
Buch MH, Mallat Z, Dweck MR, Tarkin JM, O’Regan DP, Ferreira V, et al. Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases. Nat Rev Rheumatol. (2024) 20:614–34. doi: 10.1038/s41584-024-01149-x
Porsch F, Mallat Z, Binder CJ. Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies. Cardiovasc Res. (2021) 17 (13):2544–62. doi: 10.1093/cvr/cvab285
Deroissart J, Binder CJ, Porsch F. Role of antibodies and their specificities in atherosclerotic cardiovascular disease. Arterioscler Thromb Vasc Biol. (2024) 44:2154–68. doi: 10.1161/ATVBAHA.124.319843
Conflict of interest statement
HH is director of CellTrend, GmBH. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author JRC declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
MeSH
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
Copyright
Copyright © 2026 Miranda-Prieto, Alperi-López, Pérez-Álvarez, Suárez-Díaz, Alonso-Castro, Heidecke, Suárez, Riemekasten and Rodríguez-Carrio.